Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.
Clover Health Investments, Corp. reports developments in physician enablement technology and Medicare Advantage insurance. The company offers PPO and HMO Medicare Advantage plans and uses its Clover Assistant software platform to aggregate patient data, support clinical decision-making, and address chronic disease management for Medicare populations.
Recurring Clover Health news includes quarterly and annual results, Medicare Advantage membership trends, medical cost and profitability metrics, and guidance updates. Company updates also cover Counterpart Health, the subsidiary that extends the data-driven physician enablement platform beyond Clover’s Medicare Advantage plan, including interoperability collaborations, patient data access, and clinical research tied to conditions such as diabetes, chronic kidney disease, congestive heart failure, COPD, and preventive care.
Clover Health (Nasdaq: CLOV) commented on CMS's 2026 Medicare Advantage Star ratings, reporting 3.5 Stars for its PPO MA plans and 4.0 Stars for its HMO MA plan; these ratings affect the 2027 payment year. The company reiterated confidence in driving above‑market membership growth and expanding Adjusted EBITDA profitability through 2027, citing AI‑driven improvements in its Clover Assistant and increased physician adoption. Clover reported H1 2025 revenue +34% and membership +32% year‑over‑year and a PPO HEDIS clinical score of 4.72.
Clover Health (Nasdaq: CLOV) will release its Third Quarter 2025 financial results after market close on Tuesday, November 4, 2025. Management will host a live webcast presentation at 5:00 p.m. Eastern Time the same day to discuss business and financial performance.
Investors can register for the webcast at the registration link provided and a live and archived replay will be available from Clover Health's Investor Relations website for 12 months.
Counterpart Health (Nasdaq: CLOV) announced two senior hires to accelerate enterprise partnerships and regional adoption of its AI‑powered platform Counterpart Assistant (CA). Blaine Lindsey joins as Vice President of Enterprise Growth and Partnerships to pursue national, risk‑bearing partnerships and convert inbound demand into strategic deployments. Shannon Jacobs becomes President of Market Operations for the Gulf Region to scale operations, launch new markets, and support clinicians in underserved, high‑need areas. The appointments target faster clinician adoption of AI insights within existing workflows to identify high‑risk patients and support value‑based care at scale.
Clover Health (NASDAQ:CLOV) subsidiary Counterpart Health has announced significant enhancements to its Counterpart Assistant (CA) platform, introducing new generative AI capabilities. The upgraded system enables clinicians to interact with patient data through AI chat in a PHI-safe environment, providing instant access to medical histories and source documents.
The new features include real-time conversational AI that synthesizes information from over 100 data sources and generates pre-visit summaries. The functionality is being rolled out at no additional cost to eligible CA users within Clover's network. Dr. David Tsay, Chief Medical Officer at Counterpart Health, emphasizes how this evolution helps physicians manage data overload and focus on patient care.
Clover Health (NASDAQ:CLOV) announced that Dr. Ian Duncan, a member of Clover's Medicare Advantage Board of Directors, has been elected as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries (SOA). Dr. Duncan will become the organization's 78th President and Chair at the 2026 SOA ImpACT Annual Conference.
The SOA, established in 1889, is the world's largest actuarial professional organization with over 34,000 members. Dr. Duncan's extensive experience includes founding five companies and authoring over 80 peer-reviewed papers. He currently serves as Adjunct Professor of Actuarial Statistics at UC Santa Barbara and has significantly contributed to healthcare analytics and risk adjustment methodologies.
Clover Health (Nasdaq: CLOV) has announced the implementation of Availity Essentials, a new healthcare portal aimed at streamlining provider workflows and reducing administrative burden. The portal, powered by Availity's network connecting 3.4 million providers and 95% of health plans, offers centralized access, streamlined prior authorizations, and real-time transparency tools.
The initiative will be rolled out in phases, starting with pilot providers before expanding across Clover's network. Key features include a secure interface for managing administrative tasks, faster approval workflows, and instant eligibility verification. This development aligns with Clover's strategic initiatives to improve operational efficiency and enhance the member experience through reduced procedure codes requiring authorization and expanded electronic submissions.
Clover Health (NASDAQ:CLOV) subsidiary Counterpart Health has announced a significant upgrade to its Counterpart Assistant (CA) platform with the launch of an integrated ambient scribing solution. The AI-powered feature automatically generates visit summaries from audio conversations and integrates them directly into the clinical workflow.
The new scribing capability is being offered at no additional cost to eligible physicians using CA, making enterprise-grade technology accessible to smaller independent practices. The solution supports multilingual conversations and works across desktop and mobile devices, allowing physicians to focus more on patient care while reducing documentation burden.
Clover Health (NASDAQ:CLOV) CEO Andrew Toy testified before the U.S. House Committee on Energy and Commerce Subcommittee on Health regarding AI's role in healthcare transformation. The testimony highlighted how Clover Assistant, the company's AI platform, is delivering measurable improvements in patient care and cost reduction.
Key achievements include diagnosing diabetes 3 years earlier and chronic kidney disease 1.5 years earlier than traditional methods. For patients with congestive heart failure, the platform has demonstrated 18% fewer hospitalizations and 25% fewer readmissions, while COPD patients experienced 15% fewer hospitalizations and 18% lower 30-day readmissions.
The platform serves thousands of healthcare providers across multiple states, focusing on democratizing high-quality care by bringing sophisticated care-coordination capabilities to independent physicians, particularly in rural and underserved communities.
Clover Health (NASDAQ:CLOV) reported strong Q2 2025 results with significant growth in key metrics. The company achieved Medicare Advantage membership of 106,323, up 32% year-over-year, and total revenues of $478 million, a 34% increase. Despite posting a GAAP net loss of $11 million, Clover demonstrated operational efficiency with Adjusted EBITDA and Adjusted Net income both at $17 million.
The company's technology-first model showed clinical success, with their AI-driven Clover Assistant correlating to 15% lower hospitalizations and 18% lower readmissions for COPD patients. Management updated 2025 guidance, increasing Medicare Advantage membership expectations to 104,000-108,000 while maintaining revenue guidance of $1.8-1.875 billion and improving Adjusted SG&A projections.
Clover Health (NASDAQ:CLOV) has released a significant whitepaper demonstrating the effectiveness of its Counterpart Assistant (CA) technology in improving COPD patient outcomes. The study revealed that patients under CA-enabled primary care physicians showed 75% higher COPD diagnosis rates for new members, 18% more pulmonology visits, and notably reduced hospitalizations.
The AI-powered platform, which analyzes over 100 real-time data streams, demonstrated a 15% reduction in hospitalizations and an 18% decrease in 30-day readmissions. This marks Counterpart's fifth retrospective analysis, building on previous successful studies in heart failure, diabetes, chronic kidney disease, and medication adherence management.